AC   CVCL_1924
SY   EMT6/AR1.0; EMT6/AR 1.0
DR   ECACC; 96042327
DR   Wikidata; Q54832296
RX   PubMed=1968761;
RX   PubMed=2571735;
CC   Doubling time: 12-15 hours (ECACC).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Breed/subspecies: BALB/cCRGL.
DI   NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX   NCBI_TaxID=10090; ! Mus musculus
HI   CVCL_4173 ! EMT6/P
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 07-09-18; Version: 8
RX   PubMed=1968761; DOI=10.1038/bjc.1990.52;
RA   Twentyman P.R., Wright K.A., Fox N.E.;
RT   "Characterisation of a mouse tumour cell line with in vitro derived
RT   resistance to verapamil.";
RL   Br. J. Cancer 61:279-284(1990).
RX   PubMed=2571735; DOI=10.1093/jnci/81.20.1588;
RA   Reeve J.G., Wright K.A., Rabbitts P.H., Twentyman P.R., Koch G.;
RT   "Collateral resistance to verapamil in multidrug-resistant mouse tumor
RT   cells.";
RL   J. Natl. Cancer Inst. 81:1588-1590(1989).